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Summary. Background: The development of neutralizing
antibodies, referred to as inhibitors, against factor VIII is
a major complication associated with FVIII infusion ther-
apy for the treatment of hemophilia A (HA). Previous
studies have shown that a subset of HA patients and a low
percentage of healthy individuals harbor non-neutralizing
anti-FVIII antibodies that do not elicit the clinical mani-
festations associated with inhibitor development. Objec-
tive: To assess HA patients’ anti-FVIII antibody profiles
as potential predictors of clinical outcomes. Methods: A
fluorescence immunoassay (FLI) was used to detect anti-
FVIII antibodies in 491 samples from 371 HA patients.
Results: Assessments of antibody profiles showed that the
presence of anti-FVIII IgG1, IgG2 or IgG4 correlated qual-
itatively and quantitatively with the presence of an FVIII
inhibitor as determined with the Nijmegen–Bethesda assay
(NBA). Forty-eight patients with a negative inhibitor his-
tory contributed serial samples to the study, including
seven patients who had negative NBA titers initially and
later converted to being NBA-positive. The FLI detected
anti-FVIII IgG1 in five of those seven patients prior to
their conversion to NBA-positive. Five of 15 serial-sample
patients who had a negative inhibitor history and had anti-
FVIII IgG1 later developed an inhibitor, as compared with
two of 33 patients with a negative inhibitor history without
anti-FVIII IgG1. Conclusions: These data provide a ratio-
nale for future studies designed both to monitor the
dynamics of anti-FVIII antibody profiles in HA patients
as a potential predictor of future inhibitor development
and to assess the value of the anti-FVIII FLI as a supple-
ment to traditional inhibitor testing.
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Introduction
Hemophilia A (HA) is an X-linked inherited bleeding dis-
order in which coagulation factor VIII is absent or dys-
functional, and is most commonly treated by infusion of
plasma-derived or recombinant FVIII. A major complica-
tion associated with FVIII infusion therapy is that up to
30% of patients develop antibodies that inhibit the func-
tion of and/or induce immune-dependent clearance of the
infused product [1,2]. Anti-FVIII antibodies, referred to
as inhibitors, diminish the effectiveness of infusion ther-
apy, and, in the case of high-titer inhibitors, necessitate
the use of FVIII-bypassing agents [3] or immune toler-
ance induction therapy [4,5]. Patients who develop FVIII
inhibitors face an increased risk of bleeding complications
[6] and present substantial financial and patient manage-
ment challenges to the healthcare system [7].
The Bethesda assay [8] for measurement of FVIII inhibi-
tors was developed in 1975, and modified in 1995 to the Ni-
jmegen–Bethesda assay (NBA) [9], which is the gold
standard method in use today. The NBA utilizes the degree
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to which HA patient plasma inhibits the in vitro clotting
reaction of healthy donor plasma as a means to assign
FVIII inhibitor titers. More recently, assays utilizing chro-
mogenic substrates [10], ELISA [11,12], surface plasmon
resonance (SPR) [13,14] and fluorescent immunoassays
(FLIs) [15–19] have been developed to detect anti-FVIII
antibodies in HA patients. Many previous studies have
observed that there is some discrepancy between the results
obtained with functional assays, such as the NBA, and
those obtained with other testing methods [11,12,18].
Although the assortment of FVIII inhibitor assays all share
the common goal of identifying the presence of anti-FVIII
antibodies, they have key fundamental differences that con-
tribute to the generation of discrepant results. The NBA
and chromogenic inhibitor assay (CBA) attempt to simu-
late in vivo conditions in order to detect FVIII-specific
functional inhibition of the clotting process. For the pur-
pose of these assays, functional inhibition of FVIII-depen-
dent clotting is reflected in decreased extent or kinetics of
an in vitro clotting reaction [8,9] or the cleavage of a chro-
mogenic substrate as a surrogate for clotting activity [10],
but there is no direct measurement of FVIII-specific immu-
noreactivity. Alternatively, SPR, ELISAs and anti-FVIII
FLIs (aFVIII-FLIs) directly detect anti-FVIII antibodies,
but do so without any means to assess the detected anti-
body’s ability to inflict functional inhibition on FVIII.
These differences, as well as the lack of uniformity among
laboratories in the methods used to determine what consti-
tutes a positive reaction, make it difficult to integrate the
various test results in order to reach a definitive diagnosis
of a clinically significant inhibitor.
Previous studies utilizing direct antibody detection
methods [11–13,20,21] have shown that the Ig subtype and
subclass composition of the anti-FVIII antibody response
may be critical in assessing the clinical implications of the
immune response. These studies implicated IgG1 and IgG4
as the most common anti-FVIII antibody subclasses pres-
ent in NBA-positive patient samples. The current study
investigated the composition of the antibody response in
371 HA patients, the largest group of patients studied to
date, using an aFVIII-FLI. The study examined the preva-
lence of anti-FVIII antibodies in HA patient plasma, eval-
uated the make-up of the antibody response by IgG
subclass, and assessed the clinical relevance of antibody
subtype by evaluating the extent of correlation between
FLI results and those obtained with the NBA.
Materials and methods
Subjects
The study included 491 plasma samples from 371 HA
patients (median age, 13 years; mean age, 18.5 years)
enrolled in the Hemophilia Inhibitor Research Study [22].
Of the patients, 20.5% (n = 76) were NBA-positive, and
of the samples, 24.8% (n = 122) were NBA-positive.
Inhibitor measurements were performed with a modified
version [23] of the NBA [9]. The investigational review
boards of the Centers for Disease Control and each par-
ticipating site approved the protocol, and all participants
or parents of minors gave informed consent. Control
samples were obtained from 56 paid healthy donors.
FLI
The aFVIII-FLI is a modified version of our previously
described method [18]. Briefly, plasma samples diluted
1 : 30 in phosphate-buffered saline containing 1% dried
milk were incubated with SeroMAP beads (Luminex Cor-
poration, Austin, TX, USA) coupled to Kogenate FS
(Bayer Healthcare, Tarrytown, NY, USA). Anti-FVIII
antibodies were detected by use of serial incubations with
biotinylated anti-human Ig (anti IgG1, A-10650; anti
IgG2, 05-3540; anti IgG3, MH1532; anti IgG4, A-10663;
anti IgM, H15015; Life Technologies, Carlsbad, CA,
USA) and R-phycoerythrin-conjugated streptavidin (Jack-
son ImmunoResearch, West Grove, PA, USA) with a
Bio-Plex 200 suspension array system (Bio-Rad Laborato-
ries, Hercules, CA, USA). Results are expressed as med-
ian fluorescence intensity (MFI). The threshold for
positivity was set at two standard deviations above the
mean MFI of the results obtained for healthy donors.
Statistical analyses
Comparisons of FLI and NBA results on individual
plasma samples were made by the use of GRAPHPAD PRISM
(GraphPad Software, San Diego, CA, USA) to generate
Table 1 Summary of positive fluorescence immunoassay (FLI) results for anti-factor VIII antibodies segregated by Ig
subclass
n
% Positive for anti-FVIII by FLI
IgG1 IgG2 IgG3 IgG4 IgM*
Healthy donors 56 5.4 5.4 1.8 1.8 7.1
All HA specimens 491 40.5 17.3 6.1 26.5 3.9
NBA-negative HA specimens 369 23.3 8.9 3 6 3.3
NBA-positive HA specimens 122 92.6 42.6 15.6 88.5 5.9
Correlation of FLI and NBA 0.5438, P < 0.0001 0.3411, P < 0.0001 0.2829, P < 0.0001 0.5766, P < 0.0001 0.0643, P = 0.1589
HA, hemophilia A; NBA, Nijmegen–Bethesda assay. *n = 482 HA specimens: 364 NBA-negative, and 118 NBA-positive.
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IgG1 IgG2
Control All HA NBA neg NBA pos
Control All HA NBA neg NBA pos
Control All HA NBA neg NBA pos
Control All HA NBA neg NBA pos



























































































Fig. 1. Fluorescence immunoassay results for anti-FVIII antibodies in plasma from hemophilia A (HA) patients and healthy controls. Individ-
ual data points represent plasma samples assayed for anti-FVIII IgG1 (A), IgG2 (B), IgG3 (C), IgG4 (D), and IgM (E). Results are displayed
on a log-scale for control plasmas from healthy donors, all HA patient samples, and the subsets of HA patient samples with negative or posi-
tive Nijmegen–Bethesda assay results for each Ig measured. The dashed line, which represents the assay’s positive threshold, is two standard
deviations above the mean median fluorescence intensity of 56 control samples from healthy donors. The number of samples (N) and the per-
centage of the samples that tested positive are as indicated. *P < 0.0001; **P = 0.02.
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Spearman’s correlation coefficient and two-tailed P-val-
ues. Fisher’s exact test was used to evaluate differences in
categorical data.
Results and discussion
Characterization of anti-FVIII antibodies in the plasma of
HA patients
HA patient plasma samples were examined for the pres-
ence of anti-FVIII IgG1, IgG2, IgG3, IgG4 and IgM with
an aFVIII-FLI (Table 1; Fig. 1). IgG subclass-specific
analysis of plasma samples showed that 40.5%, 17.3%,
6.1% and 26.5% of the 491 patient samples were positive
for anti-FVIII IgG1, IgG2, IgG3, and IgG4, respectively,
as compared with 5.4% (IgG1 and IgG2) or 1.8% (IgG3
and IgG4) of healthy donor samples (IgG1 and IgG4,
P < 0.0001; IgG2, P = 0.02; IgG3, P = 0.353). Evaluation
of the IgG subclass-specific FLI results segregated by
NBA status revealed that NBA-positive samples had sig-
nificantly higher rates of positivity than NBA-negative
samples for anti-FVIII IgG1, IgG2, IgG3, and IgG4
(P < 0.0001) (Table 1; Fig. 1). Rates of anti-FVIII IgM
positivity were not significantly different between patients
(3.9%) and healthy donors (7.1%) (P = 0.285).
In order to assess the relative importance of each sub-
class of anti-FVIII IgG in patients with FVIII inhibitors,
we analyzed the IgG subclass-specific FLI results to deter-
mine the composition of the FVIII antibody response in
NBA-positive samples. The results showed that 98.4% of
the NBA-positive samples had positive FLI titers for one
or more subclasses of anti-FVIII IgG, including 13.9%
that were positive for a single subclass of anti-FVIII IgG,
and 84.4% that were positive for multiple subclasses of
anti-FVIII IgG; the remaining 1.6% had no FLI-detect-
able anti-FVIII antibodies (Table 2). All of the 120 NBA-
positive samples that also tested positive by FLI con-
tained anti-FVIII IgG1 and/or IgG4, and 101 (84.2%)
were positive for both anti-FVIII IgG1 and anti-FVIII
IgG4. Both of the NBA-positive/FLI-negative results were
obtained in samples with low-titer inhibitors (0.7 and
0.8 NBU), and one of these samples was previously
reported to a be a false positive, owing to the negative
result by CBA [18].
Linear correlations were calculated according to Spear-
man to evaluate the relationship between titers obtained
from the aFVIII-FLIs and the NBA. The aFVIII-FLI
results for anti-FVIIIIgG1 and IgG4, which were positive
in 92.6% and 88.5% of samples, respectively, showed a
strong positive correlation with NBA titers (r
[IgG1] = 0.5438, r[IgG4] = 0.5766; P < 0.0001). Correla-
tions between FLI and NBA results were weak, but sig-
nificant for anti-FVIII IgG2 (r = 0.3411; P < 0.0001) and
anti-FVIII IgG3 (r = 0.2829; P < 0.0001), whereas anti-
FVIII IgM did not show a quantitative correlation with
NBA results (Table 1).
Anti-FVIII IgG composition in serial samples from individual
HA patients
Sixteen patients showed a change in NBA inhibitor status
over the course of specimen collection. Seven of these
patients (patients 1–7) had negative NBA titers in their
initial study specimen, but later developed a positive
NBA reaction following FVIII infusion therapy for the
indicated exposure days (Table 3). Examination of FLI
results in plasma samples from these seven patients
revealed that five of them harbored one or more classes
of anti-FVIII Ig in samples prior to developing an inhibi-
tor detectable by the NBA (Table 3, patients 1–5). All of
these five patients were positive for anti-FVIII IgG1 prior
to their conversion from NBA-negative to NBA-positive;
one was also positive for anti-FVIII IgG4 (patient 5) and
one for anti-FVIII IgM (patient 4). Analysis of the FLI
results in 201 samples from all 81 patients who contrib-
uted multiple specimens (data not shown) showed that
five of 15 (33.3%) patients with a negative inhibitor his-
tory and a positive anti-FVIII IgG1 result later developed
an inhibitor, as compared with two of 33 (6.1%) patients
with a negative inhibitor history without anti-FVIII IgG1
antibodies (P = 0.0239). Patients 8–16 (Table 3) all have
a history of inhibitors, and are of interest because of the
transitory nature of their NBA positivity. It is important
to note that whereas, overall, the FLI results for anti-
FVIII IgG1, IgG2, IgG3 and IgG4 showed significant posi-
tive correlations with the NBA, FLI and NBA results in
serial samples from individual patients did not necessarily
change proportionally with time. The lack of intrapatient
consistency is probably attributable to the differing role
of kinetics in the two assays, and may also reflect changes
in the patient’s immune response over time.
Positive FLI results in samples with a corresponding
negative NBA result were present in a low percentage of
samples tested for anti-FVIII IgG24, occurring in 3–9%,
whereas disparities for anti-FVIII IgG1 were more com-
mon, with positive FLI results occurring in 23.3% of
NBA-negative samples. These discrepant results may be
caused by the presence of anti-FVIII antibodies that are
Table 2 Fluorescence immunoassay (FLI) results in 122






IgG1 IgG2 IgG3 IgG4
Negative 1.6 (2) 0 0 0 0
Positive for one
subclass of IgG
13.9 (17) 10 0 0 7
Positive for two
subclasses of IgG
40.2 (49) 49 1 1 47
Positive for three
subclasses of IgG
32.0 (39) 39 37 2 39
Positive for four
subclasses of IgG
12.3 (15) 15 15 15 15
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of insufficient titer to have an inhibitory effect on coagu-
lation in the NBA, the presence of anti-FVIII antibodies
that recognize epitopes that are insignificant for the func-
tional integrity of the FVIII molecule, or non-specific or
indirect antibody binding to the FVIII-coupled beads.
Our data on serial samples drawn from 81 patients sup-
port the first hypothesis. Although it is important to note
that patients harboring non-neutralizing antibodies may
never progress to developing an inhibitor, one-third of 15
patients who had a negative inhibitor history and were
Table 3 Anti-factor VIII fluorescence immunoassay (FLI) results on serial plasma draws from hemophilia A patients
who exhibited a change in Nijmegen-Bethesda assay (NBA) status over the course of sample collection. Positive results
are in bold
Pt. Severity Draw date
Median fluorescence intensity units (MFI)
NBU Exposure daysIgG1 IgG2 IgG3 IgG4 IgM
No history of inhibitor
1 Mild 12/5/07 5.5 4.5 5 6 11.5 0.1 0–20
9/10/08 11.5 7 7 6 84.3 0 –
9/16/09 25.5 5.5 6 5 17 0 –
4/21/10 1093.3 7 191.5 8 38 1.7 0–20
6/9/10 4646.8 46 332.3 85 60.8 1.3 –
9/21/10 386.5 7.5 20.5 96.8 29 1.8 –
2 Severe 8/9/10 22 5 4.5 3.3 39.5 0.1 0–20
10/11/10 4111.8 42.3 612 1921 34 3.2 21–50
11/18/10 827 10 28.8 1109 83.5 18.7 –
2/8/11 3352 43.5 44 1277 25.5 7.2 –
3/9/11 234.5 7.5 10.3 262 25 1.4 –
3 Severe 10/1/08 75.3 5 8 4.5 90.5 0 0–20
9/22/09 441.3 15.5 8.3 1592 85.3 13.6 0–20
4 Severe 7/23/08 37.5 8.3 5.8 6.5 746.5 0.2 0–20
7/8/09 16.8 5.8 5.8 4 69 0 –
6/2/10 240.5 9 8 792.3 173.8 3.9 21–50
5 Severe 8/6/08 33 6 3.5 9 25.5 0.3 21–100
8/12/09 48.5 12.8 6.5 14.5 53.8 1.4 >150
8/14/09 11 6 3.5 10.5 46 1.4 –
6/30/10 6 6.8 4 3.5 58.8 0 –
6 Mild 3/3/10 10.5 4.3 6 4.5 109.3 0.1 0–20
5/27/10 504.8 11.8 73.5 12.3 597.5 1.4 0–20
6/14/10 3914.5 111.3 746.8 114.5 103 1.7 –
11/14/12 7.5 5.5 5 4.5 70.8 0.1 –
7 Severe 2/5/07 7 4.5 3.5 4 ND 0 101–150
6/18/08 34 6.8 4.8 1193.8 39 6.5 101–150
6/17/09 51.5 7 6.8 1276.5 248.8 3.8 –
Previous history of inhibitor
8 Severe 7/5/06 249.5 12 13 8548.3 32 19.3 ND
7/23/08 7 5.5 5 5 42 0.2 –
9 Severe 3/15/06 10 5.3 4 11.5 231 0.5 ND
5/7/08 14.5 6.3 6.5 18.5 110.3 0 –
5/6/09 9 8 5.8 7 93.8 0 –
10 Severe 9/5/07 157.3 11 6.8 27 26.5 1.1 ND
9/5/12 41 6.3 5.5 27.3 16 0.4 –
11 Severe 6/17/08 35.8 5.8 6.5 39.5 42.5 0.5 ND
6/17/09 38.5 10.5 8.5 21 15.8 0.3 –
6/16/10 19.5 4.5 5.5 22.5 25 0.3 –
12 Severe 4/12/06 15.5 4 4.5 4 54.8 0.5 ND
4/23/08 16.5 6 4 6 15.5 0.4 –
4/29/09 8 8.5 5 4 46.5 0 –
13 Mild 12/15/08 66.3 96.5 12 542 37 0.8 ND
3/4/09 10.8 58.3 6.5 14 40.5 0 –
14 Severe 11/16/07 85.5 10 5.8 1527 15 24.6 ND
9/25/09 14.5 5 4 9.8 37 0.3 –
6/2/10 337.5 92.3 398.5 145.8 95.5 3.3 –
15 Severe 2/6/08 240.8 55.5 1341.5 85.3 41.5 3.9 ND
4/8/09 16 6.5 14.5 69 23.5 0.2 –
16 Severe 10/10/07 48 25 31 510 20.8 0.3 ND
12/5/08 13.3 9 7 207.5 26.5 0.6 –
Threshold for positivity 14.6* 16.1* 75.5* 8.3* 153.6* 0.5 –
NBU, Nijmegen-Bethesda units; ND, No data collected; *Mean + 2 standard deviations of 56 healthy donors.
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positive for IgG1 converted from NBA-negative to NBA-
positive over the course of the sample collection, as com-
pared with only 6.1% of patients with a negative inhibitor
history without anti-FVIII IgG1. These findings, although
preliminary, suggest that NBA-negative patients with
anti-FVIII IgG1 are more likely to develop inhibitors
detectable by the NBA than patients without such anti-
bodies, and that these patients may merit closer scrutiny
(e.g. patients undergoing surgical procedures) or more fre-
quent follow-up testing (e.g. patients receiving initial
FVIII infusions) to facilitate prompt clinical intervention.
The identification of anti-FVIII antibodies in HA
patients is an important clinical development, but the
results presented here and by others have shown that the
mere presence of antibodies does not always correlate
with the clinical manifestations of FVIII inhibition
[11,12,16–19,24,25]. Identifying the underlying features
that distinguish cases of benign and/or transient anti-
FVIII antibodies from those that are clinically relevant
anti-FVIII inhibitors is an important area of research.
Although it remains unclear why the presence of certain
antibody subclasses may be predictive of a worse clinical
outcome, the data presented herein support those from a
recently published study by Whelan et al. [12], in which
the authors used an ELISA to show that anti-FVIII IgG1
and IgG4 were present in 19 of 20 inhibitor-positive HA
patients. They also found that anti-FVIII IgG4 was com-
pletely absent in 77 non-inhibitor patients and 600
healthy individuals, and that anti-FVIII IgG1 was present
in 19% and 6% of non-inhibitor HA patients and healthy
individuals, respectively [12]. Whelan et al. hypothesized
that their data could indicate the presence of variations in
immune regulatory pathways in the different study
cohorts. Previous studies that examined the potential link
between single-nucleotide polymorphisms in immune
response genes and a predisposition to inhibitor develop-
ment [26–30] and the results from the current study, with
a larger patient population using a different methodology,
support this hypothesis. In addition, our data illustrate
that anti-FVIII IgG4 may be present in a low percentage
of patients lacking inhibitors, as measured with the NBA,
including 2.5% (7/283) of patients with a negative inhibi-
tor history (data not shown), and that anti-FVIII IgG1
production may be an early checkpoint in inhibitor devel-
opment. Taken together, these data provide a rationale
for future clinical studies designed to monitor the dynam-
ics of HA patients’ anti-FVIII antibody profiles in order
to assess their value as predictors of the future develop-
ment of clinically relevant inhibitors and to determine the
usefulness of the aFVIII-FLI as a supplement to tradi-
tional inhibitor testing methods.
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